|
|
|
This is the preliminary program for the 2009 Joint Statistical
Meetings in Washington, DC.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2009 Program page |
= Applied Session,
= Theme Session,
= Presenter
377
|
Tue, 8/4/09, 2:00 PM - 3:50 PM | CC-201 |
| Application of Innovative Design and Analysis in Clinical Trials - Contributed - Papers | ||
|
Biopharmaceutical Section |
||
| Chair(s): Dionne Price, FDA | ||
| 2:05 PM |
Primary Efficacy Endpoint in Clinical Trials of Antiepileptic Drugs: Change or Percent Change —  Ohidul Siddiqui, FDA
|
|
| 2:20 PM |
A Methodological Perspective of Predicting Circadian Fluctuations of 24-Hour Ambulatory Blood Pressure: A New Look to ABPM Analyses in Cardiovascular Clinical Trials — D. Das Purkayastha, Novartis Pharmaceuticals
|
|
| 2:35 PM |
Flexibility and Integrity Planning in Phase IIb, 2-Stage Adaptive Dose-Ranging Acute Migraine Trials — Christopher Assaid, Merck & Co., Inc.; Frank (Xiaoyin) Fan, Merck & Co., Inc.; Joy (Yang) Ge, Merck Research Laboratories
|
|
| 2:50 PM |
Effects of Sources of Variability on Sample Sizes Required for RCTs, Applied to Trials of Lipid-Altering Therapies on Carotid Artery Intima-Media Thickness (cIMT) — A. Lawrence Gould, Merck Research Laboratories; Joerg Koglin, Merck Research Laboratories; Ray Bain, Merck Research Laboratories; Cathy-Anne Pinto, Merck Research Laboratories; Yale B. Mitchel, Merck Research Laboratories; Richard C. Pasternak, Merck Research Laboratories
|
|
| 3:05 PM |
Design of Early Treatment Trials in Alzheimer's Disease Through Cohort Enrichment and Surrogate Endpoints — Eric A. Macklin, Massachusetts General Hospital/Harvard Medical School; Deborah L. Blacker, Massachusetts General Hospita/Harvard Medical School; Bradley T. Hyman, Massachusetts General Hospital/Harvard Medical School; Rebecca Betensky, Harvard School of Public Health
|
|
| 3:20 PM |
The Use of the Third Quartile of Placebo Responses in Assessment of Drug Abuse Potential — Ling Chen, FDA
|
|
| 3:35 PM |
Modeling Smoking Cessation Data with Alternating States and a Cure Fraction Using Frailty Models — Yimei Li, University of Pennsylvania; Paul E. Wileyto, University of Pennsylvania; Daniel F. Heitjan, University of Pennsylvania
|
|
|
JSM 2009
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |